- Home
- ELVN
as 07-26-2024 4:00pm EST
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $33.00 | AVG Volume (30 days): | 362.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.80 - $26.19 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heyman Richard A. | ELVN | Director | Jul 15 '24 | Sell | $24.80 | 1,270 | $31,496.76 | 133,345 | SEC Form 4 |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jul 12 '24 | Sell | $25.01 | 1,547 | $38,692.17 | 344,027 | SEC Form 4 |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jul 12 '24 | Sell | $25.05 | 30,978 | $776,039.17 | 345,574 | SEC Form 4 |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jul 12 '24 | Sell | $25.07 | 17,475 | $438,094.76 | 376,552 | SEC Form 4 |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jul 1 '24 | Sell | $22.89 | 12,000 | $274,736.40 | 1,105,035 | SEC Form 4 |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Jun 27 '24 | Sell | $23.43 | 1,140 | $26,711.11 | 0 | SEC Form 4 |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Jun 27 '24 | Sell | $22.58 | 1,830 | $41,313.35 | 1,140 | SEC Form 4 |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Jun 27 '24 | Sell | $21.79 | 1,280 | $27,897.09 | 2,970 | SEC Form 4 |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Jun 25 '24 | Sell | $22.30 | 578 | $12,887.09 | 1,075,525 | SEC Form 4 |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Jun 25 '24 | Sell | $21.63 | 11,422 | $247,014.46 | 1,076,103 | SEC Form 4 |
| Heyman Richard A. | ELVN | Director | Jun 17 '24 | Sell | $21.48 | 1,270 | $27,277.95 | 134,615 | SEC Form 4 |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jun 6 '24 | Sell | $20.06 | 1,133 | $22,722.43 | 0 | SEC Form 4 |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 29 '24 | Sell | $21.56 | 9,877 | $212,987.63 | 2,123 | SEC Form 4 |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 29 '24 | Sell | $22.52 | 2,123 | $47,812.51 | 0 | SEC Form 4 |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 28 '24 | Sell | $24.34 | 100 | $2,434.00 | 0 | SEC Form 4 |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 28 '24 | Sell | $23.57 | 5,219 | $123,019.66 | 100 | SEC Form 4 |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 28 '24 | Sell | $22.86 | 6,681 | $152,756.39 | 5,319 | SEC Form 4 |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | May 28 '24 | Sell | $23.42 | 2,334 | $54,658.55 | 10 | SEC Form 4 |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | May 28 '24 | Sell | $24.34 | 10 | $243.40 | 0 | SEC Form 4 |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | May 28 '24 | Sell | $22.89 | 1,906 | $43,628.34 | 2,344 | SEC Form 4 |
| Gupta Rishi | ELVN | Director10% Owner | May 16 '24 | Sell | $22.14 | 1,000,000 | $22,140,000.00 | 7,663,349 | SEC Form 4 |
| Gupta Rishi | ELVN | Director10% Owner | May 16 '24 | Sell | $22.14 | 33,300 | $737,262.00 | 254,814 | SEC Form 4 |
| ORBIMED ADVISORS LLC | ELVN | Director10% Owner | May 16 '24 | Sell | $22.14 | 33,300 | $737,262.00 | 254,814 | SEC Form 4 |
| ORBIMED ADVISORS LLC | ELVN | Director10% Owner | May 16 '24 | Sell | $22.14 | 1,000,000 | $22,140,000.00 | 7,663,349 | SEC Form 4 |
| Heyman Richard A. | ELVN | Director | May 16 '24 | Sell | $23.74 | 1,270 | $30,149.67 | 135,885 | SEC Form 4 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Enliven Therapeutics Insider Sold Shares Worth $1,252,826, According to a Recent SEC Filing
MT Newswires
a month ago
Enliven Therapeutics Insider Sold Shares Worth $259,902, According to a Recent SEC Filing
GlobeNewswire
2 months ago
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
MT Newswires
2 months ago
Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing
MT Newswires
2 months ago
Enliven Therapeutics Q1 Loss Narrows
GlobeNewswire
2 months ago
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Barrons.com
3 months ago
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
Benzinga
3 months ago
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.